2020 Revenues ($USD) : $4,017,120,014
2020 Revenues (foreign currencies) : RMB27,735,000,000
2020 R&D spend : $722,603,633
2020 Number of Employees : 28,903
Fiscal Year End : 12/31/2020
Key People : Zhou Yunshu, chair & president

Publicly traded on the Shanghai Stock Exchange, Jiangsu Hengrui Medicine boasts over 100 pipelines and products across therapeutic areas such as oncology, metabolics, autoimmune, pain management. In China, it has established a National Targeted Drug Engineering Technology Research Center. HengRui USA’s headquarters are in Princeton, N.J. –CN